@article{CCO17213,
author = {Francesco Ricci and Christophe Le Tourneau},
title = {Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence?},
journal = {Chinese Clinical Oncology},
volume = {7},
number = {1},
year = {2017},
keywords = {},
abstract = {Human epidermal receptor growth factor 2 (HER2, ERBB2) gene amplification occurs in about 15–20% of invasive breast cancers and is associated with biologically aggressive disease and poor overall survival in the absence of systemic therapy (1). The synthesis of trastuzumab, a humanized monoclonal antibody targeting the extracellular domain of HER2, was a major leap forward in the treatment of this disease.},
issn = {2304-3873}, url = {https://cco.amegroups.org/article/view/17213}
}